{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:29:56Z","timestamp":1791462596777,"version":"4.3.4"},"reference-count":38,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"unspecified","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["802544"],"award-info":[{"award-number":["802544"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Norwegian Health Region South-East","award":["2017100"],"award-info":[{"award-number":["2017100"]}]},{"name":"Norwegian Ministry of Health and Care Services","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100031365","name":"Oslo universitetssykehus HF","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100031365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,7,8]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fecal microbiota transplantation (FMT) has shown promise in overcoming resistance to immune checkpoint inhibitors (ICIs) in early-phase cancer trials. We investigated the safety, feasibility and efficacy of FMT from ICI responders to patients with advanced cancers progressing on ICIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This was a single-arm phase IIa basket trial (MITRIC;\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05286294\">NCT05286294<\/jats:ext-link>\n                      ) including patients with ICI-refractory cancer. Long-term ICI responders were used as FMT donors. Patients received FMTs in combination with ICIs; two FMT administrations (by colonoscopy) were scheduled before the first radiological evaluation after 6 weeks, and up to three later FMTs were allowed (by enema). Co-primary endpoints were the evaluation of FMT-related adverse events and objective response rate. Feasibility, clinical benefit rate, progression-free survival (PFS), overall survival (OS), implant engraftment, immune response and biomarkers were among the secondary objectives.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study enrolled 12 patients with melanoma (n=9), head and neck squamous cell carcinoma (HNSCC; n=1), renal cell carcinoma (n=1) or microsatellite instability-high pancreatic cancer (n=1). FMT was well tolerated, whereas immune-related toxicity occurred in 6\/12 patients. All patients received the first FMT; 10\/12 patients also underwent the second FMT. No objective responses were observed, while 5\/12 patients recorded stable disease. Clinical benefit per-protocol (stable disease &gt;6 months) was achieved in a patient with melanoma, who had regression of some lesions and remains alive after 33 months without further systemic treatment. Mixed responses with regression of some lesions were observed in another melanoma patient, and in a patient with HNSCC. The median PFS was 1.5 months, and median OS was 10.1 months. Sequencing of fecal samples indicated engraftment after the first FMT in most patients. Mass cytometry analysis of peripheral blood cells suggested that an activated and differentiated T-cell signature was associated with improved PFS and OS, while a na\u00efve T-cell phenotype and a myeloid-dominant environment were unfavorable. CD14\n                      <jats:sup>+<\/jats:sup>\n                      monocytes and serum interleukin-8 increased at group level over time.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>FMT in combination with ICIs was safe and feasible in patients with advanced cancers, but with limited clinical activity. Further studies are required to clarify the potential benefit of FMT, identify the appropriate patient population and define criteria for donor selection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05286294\">NCT05286294<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2026-015122","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:00:14Z","timestamp":1784556014000},"page":"e015122","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Safety and efficacy of fecal microbiota transplantation in solid cancers resistant to immune checkpoint inhibitors: results of the MITRIC trial"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct05286294","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05286294","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05286294","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Andreas","family":"Ullern","sequence":"first","affiliation":[{"name":"Department of Clinical Cancer Research, Oslo University Hospital, Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjetil Kjelstad","family":"Garborg","sequence":"additional","affiliation":[{"name":"Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway"},{"name":"University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7931-8518","authenticated-orcid":false,"given":"Sudhir Kumar","family":"Chauhan","sequence":"additional","affiliation":[{"name":"Department of Cancer Immunology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Holm","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Bang","sequence":"additional","affiliation":[{"name":"Institute of Clinical Molecular Biology, Christian-Albrechts-Universitat of Kiel, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Dunn","sequence":"additional","affiliation":[{"name":"Department of Cancer Immunology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Holger","family":"Johnsen","sequence":"additional","affiliation":[{"name":"University Hospital of North Norway, Troms\u00f8, Norway"},{"name":"UiT The Arctic University of Norway, Troms\u00f8, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes Espolin Roksund","family":"Hov","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway"},{"name":"Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2854-3694","authenticated-orcid":false,"given":"Jon Amund","family":"Kyte","sequence":"additional","affiliation":[{"name":"Department of Clinical Cancer Research, Oslo University Hospital, Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Cancer Immunology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"2026072007000859000_14.7.e015122.1","doi-asserted-by":"crossref","DOI":"10.1172\/JCI184846","article-title":"Checkpoint therapy in cancer treatment: progress, challenges, and future directions","volume":"134","author":"Bicak","year":"2024","journal-title":"J Clin Invest"},{"key":"2026072007000859000_14.7.e015122.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2407417"},{"key":"2026072007000859000_14.7.e015122.3","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35347"},{"key":"2026072007000859000_14.7.e015122.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.03.006"},{"key":"2026072007000859000_14.7.e015122.5","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011929","article-title":"SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy","volume":"13","author":"Sullivan","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026072007000859000_14.7.e015122.6","doi-asserted-by":"publisher","DOI":"10.1126\/science.aac4255"},{"key":"2026072007000859000_14.7.e015122.7","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad1329"},{"key":"2026072007000859000_14.7.e015122.8","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan3706"},{"key":"2026072007000859000_14.7.e015122.9","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan4236"},{"key":"2026072007000859000_14.7.e015122.10","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao3290"},{"key":"2026072007000859000_14.7.e015122.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01406-6"},{"key":"2026072007000859000_14.7.e015122.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.05.029"},{"key":"2026072007000859000_14.7.e015122.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00785-8"},{"key":"2026072007000859000_14.7.e015122.14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01695-5"},{"key":"2026072007000859000_14.7.e015122.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01698-2"},{"key":"2026072007000859000_14.7.e015122.16","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1200\/JCO-25-00374","article-title":"Microbiome Modulation for the Treatment of Solid Neoplasms","volume":"43","author":"Barragan-Carrillo","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026072007000859000_14.7.e015122.17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1146\/annurev-immunol-082323-114522","article-title":"Harnessing the Microbiome in Cancer Immunotherapy: Regulation, Prediction, and Therapeutic Targeting","volume":"44","author":"Zarour","year":"2026","journal-title":"Annu Rev Immunol"},{"key":"2026072007000859000_14.7.e015122.18","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf3363"},{"key":"2026072007000859000_14.7.e015122.19","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb5920"},{"key":"2026072007000859000_14.7.e015122.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2024.06.010"},{"key":"2026072007000859000_14.7.e015122.21","doi-asserted-by":"crossref","first-page":"103025","DOI":"10.1016\/j.ctrv.2025.103025","article-title":"Fecal microbiota transplantation to enhance cancer treatment outcomes across different cancer types: A systematic literature review","volume":"140","author":"Wekking","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"2026072007000859000_14.7.e015122.22","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-319548"},{"key":"2026072007000859000_14.7.e015122.23","doi-asserted-by":"crossref","DOI":"10.1186\/s12876-023-02979-x","article-title":"Colonic distribution of FMT by different enema procedures compared to colonoscopy - proof of concept study using contrast fluid","volume":"23","author":"Skjevling","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"2026072007000859000_14.7.e015122.24","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/1878-0261.13760","article-title":"Gut microbiota diversity is prognostic and associated with benefit from chemo-immunotherapy in metastatic triple-negative breast cancer","volume":"19","author":"Ullern","year":"2025","journal-title":"Mol Oncol"},{"key":"2026072007000859000_14.7.e015122.25","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/1878-0261.70117","article-title":"Gut microbiota diversity is prognostic in metastatic hormone receptor-positive breast cancer patients receiving chemotherapy and immunotherapy","volume":"20","author":"Ullern","year":"2026","journal-title":"Mol Oncol"},{"key":"2026072007000859000_14.7.e015122.26","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-024-00638-2","article-title":"Peripheral immune cells in metastatic breast cancer patients display a systemic immunosuppressed signature consistent with chronic inflammation","volume":"10","author":"Chauhan","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"2026072007000859000_14.7.e015122.27","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2024.2440967","article-title":"Plasma protein dynamics during ipilimumab treatment in metastatic melanoma: associations with tumor response, adverse events and survival","volume":"14","author":"Lereim","year":"2025","journal-title":"Oncoimmunology"},{"key":"2026072007000859000_14.7.e015122.28","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30074-8"},{"key":"2026072007000859000_14.7.e015122.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2026072007000859000_14.7.e015122.30","unstructured":"R Core Team . R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2023."},{"key":"2026072007000859000_14.7.e015122.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910437"},{"key":"2026072007000859000_14.7.e015122.32","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16148"},{"key":"2026072007000859000_14.7.e015122.33","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02453-x"},{"key":"2026072007000859000_14.7.e015122.34","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/s41591-025-04183-8","article-title":"Fecal microbiota transplantation plus immunotherapy in metastatic renal cell carcinoma: the phase 1 PERFORM trial","volume":"32","author":"Fernandes","year":"2026","journal-title":"Nat Med"},{"key":"2026072007000859000_14.7.e015122.35","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/s41591-025-04189-2","article-title":"Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial","volume":"32","author":"Porcari","year":"2026","journal-title":"Nat Med"},{"key":"2026072007000859000_14.7.e015122.36","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/s41591-025-04186-5","article-title":"Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial","volume":"32","author":"Duttagupta","year":"2026","journal-title":"Nat Med"},{"key":"2026072007000859000_14.7.e015122.37","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012659","article-title":"Improved survival in advanced melanoma patients treated with fecal microbiota transplantation using healthy donor stool in combination with anti-PD1: final results of the MIMic phase 1 trial","volume":"13","author":"Hadi","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026072007000859000_14.7.e015122.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.016"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-015122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:00:26Z","timestamp":1784556026000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-015122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":38,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,20]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/jitc-2026-015122"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-015122","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}